Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Stoke Therapeutics, Inc. shareholders approved Election of three Class I directors: Adrian R. Krainer, Ph.D., Garry E. Menzel, Ph.D. and Julie Anne Smith at the 2023-06-13 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-13
Exact text from the filing
Election of three Class I directors, Adrian R. Krainer, Ph.D., Garry E. Menzel, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified: Nominees Shares For Shares Withheld/Abstaining Broker Non-Votes Adrian R. Krainer, Ph.D. 23,672,988 7,986,841 3,838,508 Garry E. Menzel, Ph.D. 25,992,037 5,667,792 3,838,508 Julie Anne Smith 30,318,661 1,341,168 3,838,508
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Stoke Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation at the 2023-06-13 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-13
Exact text from the filing
Approval of an amendment to the Company’s Certificate of Incorporation: Shares For Shares Against Shares Withheld/Abstaining 27,025,612 4,629,558 4,659
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Stoke Therapeutics, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-13 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-13
Exact text from the filing
Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Withheld/Abstaining 35,481,487 15,863 987
View on SEC.gov